Beximco Pharmaceuticals Limited Overview
Get informed when a big investor buys or sells
+ Follow5.20
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Beximco Pharmaceuticals Limited (BXP.L) currently reports a P/E ratio of 5.2. That is below the sector sector average of 22.73. Use the charts on this page to explore Beximco Pharmaceuticals Limited's P/E ratio history and peer comparisons.
Beximco Pharmaceuticals Limited's P/E ratio of 5.2 is lower than the its sector sector average of 22.73. That is roughly 77.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Beximco Pharmaceuticals Limited's market price to a fundamental measure such as earnings, sales, or book value. At 5.2, BXP.L can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 5.2, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 22.73. From there, open related valuation or income-statement pages for Beximco Pharmaceuticals Limited, and consider following BXP.L for alerts when major investors trade the stock.
